- Home
- BTBT vs ZNTL Comparison
BTBT vs ZNTL Comparison
Compare BTBT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBT
- ZNTL
- Stock Information
- Founded
- BTBT 2015
- ZNTL 2014
- Country
- BTBT United States
- ZNTL United States
- Employees
- BTBT N/A
- ZNTL N/A
- Industry
- BTBT Finance: Consumer Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- BTBT Finance
- ZNTL Health Care
- Exchange
- BTBT Nasdaq
- ZNTL Nasdaq
- Market Cap
- BTBT 437.8M
- ZNTL 105.8M
- IPO Year
- BTBT 2018
- ZNTL 2020
- Fundamental
- Price
- BTBT $2.13
- ZNTL $1.20
- Analyst Decision
- BTBT Strong Buy
- ZNTL Buy
- Analyst Count
- BTBT 3
- ZNTL 7
- Target Price
- BTBT $6.33
- ZNTL $8.60
- AVG Volume (30 Days)
- BTBT 20.3M
- ZNTL 1.4M
- Earning Date
- BTBT 08-18-2025
- ZNTL 08-08-2025
- Dividend Yield
- BTBT N/A
- ZNTL N/A
- EPS Growth
- BTBT N/A
- ZNTL N/A
- EPS
- BTBT N/A
- ZNTL N/A
- Revenue
- BTBT $102,037,923.00
- ZNTL $26,865,000.00
- Revenue This Year
- BTBT $31.34
- ZNTL N/A
- Revenue Next Year
- BTBT $40.97
- ZNTL N/A
- P/E Ratio
- BTBT N/A
- ZNTL N/A
- Revenue Growth
- BTBT 52.44
- ZNTL N/A
- 52 Week Low
- BTBT $1.69
- ZNTL $1.01
- 52 Week High
- BTBT $5.74
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- BTBT 35.84
- ZNTL 43.44
- Support Level
- BTBT $2.18
- ZNTL $1.31
- Resistance Level
- BTBT $2.51
- ZNTL $1.39
- Average True Range (ATR)
- BTBT 0.15
- ZNTL 0.13
- MACD
- BTBT -0.06
- ZNTL -0.02
- Stochastic Oscillator
- BTBT 12.79
- ZNTL 6.83
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.